Nanobiotix Secures €85M for JNJ-1900 (NBTXR3) Trials

Nanobiotix has completed a €85 million global equity offering, securing vital capital for its oncology pipeline, with a significant focus on its lead product candidate, JNJ-1900 (NBTXR3). This funding comes on the heels of encouraging Phase 2 trial data for JNJ-1900 in treating stage 3 inoperable non-small cell lung cancer, data which was presented at ESTRO 2026.

The capital will be strategically deployed to progress Nanobiotix's oncology development. The equity raise, priced around €33.60 per share, indicates strong investor demand, including from US-based investors and those utilizing American Depositary Shares and pre-funded warrants. This financial backing underscores market confidence in Nanobiotix's late-stage pipeline and earlier platforms.

Investors are now closely monitoring Nanobiotix's execution on both clinical and operational fronts. As more data emerges for JNJ-1900 (NBTXR3) and the newly raised funds are utilized, the market will look for clarity on development timelines, regulatory interactions, and potential future collaborations or financing. This successful funding round, coupled with promising trial results, signals a readiness to finance the company's ambitious growth strategy, albeit with some dilution for existing shareholders.